NAVB Navidea Biopharmaceuticals Inc

Price (delayed)

$1.95

Market cap

$56.6M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.46

Enterprise value

$49.8M

Highlights
The company's debt fell by 47% QoQ and by 26% YoY
NAVB's EPS is up by 32% YoY and by 4.2% from the previous quarter
Navidea Biopharmaceuticals's revenue has increased by 14% YoY but it has decreased by 3.6% from the previous quarter
The company's gross profit rose by 14% YoY but it fell by 3.5% QoQ
The company's net income fell by 2.7% QoQ

Key stats

What are the main financial stats of NAVB
Market
Shares outstanding
29.03M
Market cap
$56.6M
Enterprise value
$49.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.02
Price to sales (P/S)
62.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
56.43
Earnings
Revenue
$882,478
EBIT
-$11.03M
EBITDA
-$10.8M
Free cash flow
-$10.41M
Per share
EPS
-$0.46
Free cash flow per share
-$0.37
Book value per share
$0.15
Revenue per share
$0.03
TBVPS
$0.33
Balance sheet
Total assets
$10.08M
Total liabilities
$5.07M
Debt
$704,251
Equity
$4.28M
Working capital
$4.67M
Liquidity
Debt to equity
0.16
Current ratio
2.12
Quick ratio
1.81
Net debt/EBITDA
0.63
Margins
EBITDA margin
-1,224.3%
Gross margin
100%
Net margin
-1,248.2%
Operating margin
-1,288.4%
Efficiency
Return on assets
-151%
Return on equity
-1,370.3%
Return on invested capital
-18,490.7%
Return on capital employed
-186.3%
Return on sales
-1,249.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NAVB stock price

How has the Navidea Biopharmaceuticals stock price performed over time
Intraday
-2.01%
1 week
1.56%
1 month
21.88%
1 year
-45.22%
YTD
-9.3%
QTD
-3.47%

Financial performance

How have Navidea Biopharmaceuticals's revenue and profit performed over time
Revenue
$882,478
Gross profit
$882,039
Operating income
-$11.37M
Net income
-$11.01M
Gross margin
100%
Net margin
-1,248.2%
Navidea Biopharmaceuticals's revenue has increased by 14% YoY but it has decreased by 3.6% from the previous quarter
The company's gross profit rose by 14% YoY but it fell by 3.5% QoQ
The company's net margin rose by 14% YoY but it fell by 7% QoQ
NAVB's operating margin is up by 11% year-on-year but it is down by 10% since the previous quarter

Growth

What is Navidea Biopharmaceuticals's growth rate over time

Valuation

What is Navidea Biopharmaceuticals stock price valuation
P/E
N/A
P/B
13.02
P/S
62.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
56.43
NAVB's EPS is up by 32% YoY and by 4.2% from the previous quarter
NAVB's price to sales (P/S) is 23% less than its last 4 quarters average of 80.1
Navidea Biopharmaceuticals's revenue has increased by 14% YoY but it has decreased by 3.6% from the previous quarter

Efficiency

How efficient is Navidea Biopharmaceuticals business performance
The company's return on assets rose by 27% YoY and by 16% QoQ
NAVB's ROS is up by 14% YoY but it is down by 7% from the previous quarter

Dividends

What is NAVB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NAVB.

Financial health

How did Navidea Biopharmaceuticals financials performed over time
The company's total assets is 99% higher than its total liabilities
The current ratio has soared by 168% YoY and by 54% from the previous quarter
The company's total assets has surged by 125% YoY and by 30% QoQ
The company's debt is 84% lower than its equity
NAVB's debt to equity has surged by 130% year-on-year but it has dropped by 84% since the previous quarter
The company's debt fell by 47% QoQ and by 26% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.